Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $1.1752W HIGH $13.25
Volume
10.71 K
Value Traded
16.49 K
Short % Float
0.88%
Days to Cover
1.0
+3.06%Week
+0.33%1 Month
-9.28%3 Month
-52.36%6 Month
-99.99%5 Year
-100%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
6.78 M
EPS (TTM)
-1.95
P/E Ratio
-
Ent. Value
-1.54 M
Total Shares
4.48 M
Float Shares
4.40 M
Insiders
1.64%
Institutions
11.85%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
ENVB Catalyst Timeline
Dated clinical, regulatory and corporate events for Enveric Biosciences, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Enveric Biosciences, Inc.
272Total events
8Upcoming
37Tier-1 (high impact)
2005 to 2027Coverage
Upcoming catalysts 2
Event history 50
▲Preclinical PoCEB-003Preclinical
Positive IND-enabling in vitro ADMET results for EB-003 (over 70 assays)
psychiatric and neurological disorderssource ↗
▲Patent GrantedIP / Competition
USPTO Notice of Allowance for EVM401 Series mescaline derivative patent application
post-traumatic stress disorder (PTSD) and other psychiatric disorderssource ↗
▲Preclinical PoCEB-003Preclinical
GloSensor cAMP assay results support non-hallucinogenic profile of EB-003
▲FDA Feedback ReceivedFDA Meeting
FDA released final guidance for psychedelic drug development
◆Oral PresentationPresentation
Participation in B. Riley Securities Mind, Muscle & Vision Summit
▲Preclinical PoCEB-003Preclinical
Positive results for EB-003 indicating rapid reduction in conditioned fear response in preclinical PTSD model
PTSDsource ↗
▼Equity OfferingCorporate
Raised additional approximately $1.5 million from exercise of warrants
◆Oral PresentationPresentation
Participation in B. Riley Securities Mind, Muscle & Vision Summit
●IND Enabling CompleteEB-003Preclinical
Initiation of IND-enabling genotoxicity studies for EB-003
▲Preclinical PoCEB-003Preclinical
Positive preclinical phototoxicity analysis results for EB-003
●Runway Guidance UpdateCorporate
Cash balance of approximately $10.3 million as of May 15, 2026, expected to support operations into Q1 2027
▲Patent GrantedIP / Competition
U.S. patent issued for methods of treating psychiatric disorders
psychiatric disorderssource ↗
●Oral PresentationPresentation
CEO to participate in panel at Needham Virtual Psychedelics Forum
▼Equity OfferingCorporate
Closing of $5 million private placement with up to $8.9 million additional warrant proceeds
▼Equity OfferingCorporate
Up to $13.9 million private placement priced at-the-market under Nasdaq rules
▲Preclinical PoCEB-003Preclinical
EB-003 non-hallucinogenic profile in GloSensor assay
neuropsychiatric disorderssource ↗
●IND Enabling CompleteEB-003Preclinical
Initiation of genotoxicity studies for EB-003
neuropsychiatric disorderssource ↗
▲Patent GrantedIP / Competition
Notice of Allowance for EVM401 Series patent application
mental health disorderssource ↗
▲Preclinical PoCEB-003Preclinical
Reported additional preclinical data for EB-003 demonstrating dual Gq and β-arrestin signaling at 5-HT2A
▲Patent GrantedIP / Competition
New patent issuances and allowances across EVM301 and EVM401 series
▲IP Litigation RulingIP / Competition
Withdrawal by AbbVie of Post-Grant Review petition against Enveric's U.S. Patent No. 12,138,276
▼Equity OfferingCorporate
Raised gross proceeds of approximately $1.5 million through registered direct offering
▲Partnership / LicenseCorporate
Expanded collaboration with TOTEC Pharma through trademark license and option, out-licensing RCANN™ trademark portfolio
▲Patent GrantedEB-003IP / Competition
U.S. Patent No. 12,577,232 issued for EVM301 Series covering EB-003
mental health disorderssource ↗
▲IP Litigation RulingIP / Competition
PTAB grants withdrawal of PGR petition against '276 patent
▼Equity OfferingCorporate
Registered direct offering of 328,802 shares at $4.41 per share, with concurrent private placement of warrants
▲Partnership / LicenseRCANNCorporate
Enveric subsidiary Akos Biosciences licenses RCANN trademark portfolio to TOTEC Pharma with option to purchase
radiation dermatitissource ↗
◆Oral PresentationPresentation
Enveric to present and participate in panel at Sachs Associates 9th Annual Neuroscience Innovation Forum
▲Patent GrantedIP / Competition
New patent issuances and allowances across EVM301 and EVM401 series
▲Partnership / LicenseCorporate
Expanded collaboration with TOTEC Pharma through trademark license and option
▲Patent GrantedIP / Competition
Issuance of U.S. Patent No. 12,492,179 covering substituted ethylamine fused heterocyclic mescaline derivatives
neuropsychiatric conditionssource ↗
◆First Patient DosedEB-003Trial
First-in-human clinical trial initiation expected by end of 2025
severe mental health disorderssource ↗
▲Patent GrantedEVM-401IP / Competition
Fourth Notice of Allowance for EVM401 Series patent application
mental health disorderssource ↗
Past FDA Catalysts and PDUFA Decisions
How ENVB actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-09-11 | EB-003 | Pre-clinical data presentation | Pre-clinical |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Clinical Trial Results
Readouts, endpoints and source filings for every ENVB program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| EB-003 | PTSD | 2025-11-14 | significantly decreased context-induced freezing behavior one-hour post-dose (p < 0.05)Read More | Enveric Biosciences Reports Third Quarter 2025 Financial and Corporate Results In Q3, Enveric continued toward clinical readiness for lead candidate EB-003, targeting neuropsychiatric indications, announcing additional pRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| PASQUALONE FRANKDirector | Buy | 1,000 1,000 held | $2.14 | 09/15/2023 |
Hedge Fund 13F Activity
Hedge Funds invested in ENVB
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Ikarian Capital, LLC | 0 % | 138.00 K | 100.00 K | -55.32% ( -123.83 K) |
Ownership Trends
ENVB Short Interest
Shares sold short, counted twice a month.
0.88%
Short % of Float
of tradable shares sold short
38.7K
Shares Sold Short
+150.7% vs prior count
1.0 Low
Days to Cover
trading days of normal volume to buy every short share back
73.5K
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How ENVB ranks across every disease it competes in
Competitive Position is a premium feature
See how ENVB ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialENVB News
ENVB▲ +1%today
Enveric Biosciences Reports Differentiated Brain Activity Profile for EB-003 in Preclinical qEEG Study
Enveric Biosciences reported positive results from a qEEG study of EB-003, showing modulation of brain activity in prefrontal and parietal regions. The study indicated a favorable neurophysiological profile compared to DMT, with no adverse effects like epileptic activity. These findings support the use of qEEG as a biomarker in upcoming human trials.
Read more →ENVBEnveric Biosciences Announces Positive Results from Recently Completed IND-enabling ADMET Studies
Enveric Biosciences announced positive results from IND-enabling ADMET studies for EB-003, its lead candidate. The studies indicated favorable absorption, distribution, and metabolism properties. CEO Joseph Tucker emphasized the drug's potential to maintain therapeutic benefits while minimizing safety concerns. The results support the candidate's progression toward a first-in-human clinical trial.
Read more →ENVBEnveric Biosciences Secures New U.S. Patent Allowance for Next-Generation, Non-Hallucinogenic Mescaline Derivatives in EVM401 Series
Enveric Biosciences has announced the receipt of a Notice of Allowance from the USPTO for a patent application related to its EVM401 Series. This series includes novel, non-hallucinogenic mescaline derivatives aimed at addressing psychiatric and neurological disorders. The patent allowance marks a significant step in the development of these innovative therapeutics.
Read more →ENVBEnveric Biosciences to Present at H.C. Wainwright 28th Annual Global Investment Conference
Enveric Biosciences announced that its CEO, Joseph Tucker, will present at the H.C. Wainwright 28th Annual Global Investment Conference. The event is scheduled for September 14-16, 2026, in New York City. This presentation aims to showcase the company's advancements in neuroplastogenic therapeutics for psychiatric and neurological disorders.
Read more →ENVBEnveric Biosciences Reports Financial Results and Provides Corporate Update for Second Quarter 2026
Enveric Biosciences reported its financial results for Q2 2026, highlighting advancements in its development of neuroplastogenic small molecules aimed at treating psychiatric and neurological disorders. The company is preparing for its first-in-human clinical trials, indicating a positive trajectory in its research and development efforts.
Read more →ENVBEnveric Biosciences Reports New Preclinical Data Supporting the Non-Hallucinogenic Profile of Lead Candidate EB-003
Enveric Biosciences has announced new preclinical data supporting the non-hallucinogenic profile of its lead candidate, EB-003. The testing utilized a highly sensitive GloSensor™ cAMP assay, contributing to the evidence of EB-003's therapeutic potential in addressing psychiatric and neurological disorders. This development marks a significant step for the company in its research efforts.
Read more →ENVBEnveric Biosciences Welcomes Final FDA Guidance for Psychedelic Drug Development
Enveric Biosciences has welcomed the FDA's finalized guidance on psychedelic drug development, which addresses key clinical challenges. The guidance emphasizes the importance of rigorous data generation for regulatory review. Enveric's EB-003 aims to engage neuroplasticity without inducing hallucinogenic experiences, potentially allowing for simpler trial designs and outpatient treatment options. The FDA's guidance is seen as a positive step towards the practical delivery of psychedelic therapies.
Read more →ENVBEnveric Biosciences Announces Participation in B. Riley Securities Mind, Muscle & Vision Summit
Enveric Biosciences has announced its participation in the B. Riley Securities Mind, Muscle & Vision Summit. The event aims to focus on advancements in mental health and related therapies. Further details on the company's specific contributions or presentations at the summit were not provided.
Read more →ENVB▼ -7.4%on this news
Enveric Biosciences Announces Participation in 2026 BIO International Convention
Enveric Biosciences has announced its participation in the 2026 BIO International Convention. The event is expected to provide a platform for networking and showcasing advancements in biotechnology. Further details regarding their participation and planned activities at the convention were not disclosed in the announcement.
Read more →ENVB▼ -8.6%on this news
Enveric Biosciences to Participate in the UBS 3rd Virtual CNS Day
Enveric Biosciences will participate in the UBS 3rd Virtual CNS Day. The event aims to discuss advancements in central nervous system therapies. Details regarding the company's presentation or specific topics have not been disclosed.
Read more →ENVBEnveric Biosciences Initiates Investigational New Drug (IND)-enabling Genotoxicity Studies of Lead Neuroplastogen Candidate EB-003
Enveric Biosciences has commenced IND-enabling genotoxicity studies for its lead neuroplastogen candidate, EB-003. This marks a significant step in the drug development process, reflecting the company's commitment to ensuring the safety and efficacy of its therapeutic candidate. The studies are essential for regulatory approval.
Read more →ENVBEnveric Biosciences Reports Positive Preclinical Results from Phototoxicity Analysis for Lead Neuroplastogen Candidate EB-003
Enveric Biosciences has announced positive preclinical results from a phototoxicity analysis of its lead neuroplastogen candidate, EB-003. This analysis is crucial for assessing the safety profile of the compound. The encouraging findings may pave the way for further development and potential clinical trials.
Read more →ENVBEnveric Biosciences Reports Financial Results and Provides Corporate Update for First Quarter 2026
Enveric Biosciences (NASDAQ: ENVB) released its financial results and corporate updates for the first quarter of 2026, highlighting continued progress in the development of lead candidate EB-003. The company reported promising preclinical data, which suggests EB-003's effectiveness in providing rapid antidepressant and anxiolytic effects, particularly in PTSD. Additionally, Enveric has fortified its intellectual property portfolio and raised significant capital to support ongoing and future development efforts. Despite a reported net loss for the quarter, the company remains optimistic about its prospects.
Read more →ENVBEnveric Biosciences Expands IP Portfolio with New U.S. Patent Issued for Methods of Treating Psychiatric Disorders
Enveric Biosciences has announced the issuance of a new U.S. patent that expands its intellectual property portfolio. This patent pertains to methods of treating psychiatric disorders, potentially enhancing the company's capabilities in this therapeutic area. The development is expected to bolster investor confidence and support future innovations.
Read more →ENVBEnveric Biosciences Highlights Positive Results for EB-003 in PTSD Preclinical Model
Enveric Biosciences has announced positive results for its drug candidate EB-003 in a preclinical model for PTSD. The findings suggest potential efficacy, paving the way for future research and development. This advancement highlights the company's commitment to addressing PTSD through innovative therapies.
Read more →ENVB▼ -7.7%on this news· ran to +38% by day 3shared move
Enveric Biosciences to Participate in a Panel Discussion at Needham’s Virtual Psychedelics Forum
Enveric Biosciences will have its CEO, Joseph Tucker, participate in a panel at Needham's Virtual Psychedelics Forum. The discussion will focus on non-hallucinogenic treatments for psychiatric conditions, particularly in relation to treatment-resistant depression. This participation highlights the company's commitment to advancing neuroplastogenic therapeutics.
Read more →ENVB▲ +100.5%on this newsshared move
Enveric Biosciences Announces Closing of Up To $13.9 Million Private Placement Priced At-The-Market Under Nasdaq Rules
Enveric Biosciences has successfully closed a private placement, raising $5 million upfront, with potential additional proceeds of $8.9 million from warrants. The funds will be used for product development and general corporate purposes. The offering includes common stock and warrants, but there is no guarantee that the warrants will be exercised.
Read more →ENVB▼ -22.6%on this news· ran to +55% by day 1shared move
Enveric Biosciences Announces Up To $13.9 Million Private Placement Priced At-The-Market Under Nasdaq Rules
Enveric Biosciences has announced a private placement to raise up to $13.9 million, including $5 million upfront and potential additional proceeds from warrants. The offering involves the sale of shares and warrants priced at $2.25 per share. The funds will be used for product development and working capital, with the closing expected around April 17, 2026.
Read more →ENVB▲ +8.4%on this news· ran to +20% by day 1
Enveric Biosciences Secures New U.S. Patent for Its EVM301 Series of Drug Candidates
Enveric Biosciences has secured a new U.S. patent for its EVM301 Series, enhancing its intellectual property portfolio. The patent covers chemical compounds and methods for treating neurological disorders. The lead candidate, EB-003, is aimed at addressing mental health issues without hallucinogenic effects. The company is focused on advancing EB-003 towards a Phase 1 clinical trial.
Read more →ENVBEnveric Biosciences Reports Financial Results and Provides Corporate Update for Fourth Quarter and Fiscal Year Ended 2025
Enveric Biosciences reported its financial results for Q4 and the fiscal year 2025, highlighting advancements in its lead candidate EB-003, aimed at treating mental health disorders. The company is preparing for an IND application to the FDA, supported by promising research findings. However, it also noted a net loss of $4.0 million for the quarter.
Read more →About Enveric Biosciences, Inc.
Headquarters245 FIRST STREET RIVERVIEW II 18TH FLOOR, CAMBRIDGE, MA, 02142
BIOPHARMAWATCH ELITE PLUS
Trade the next ENVB catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime